The company has ditched a trial of drebuxelimab plus ivonescimab.
ApexOnco Front Page
Recent articles
CRB-601 and PF-06940434 fall by the wayside.
Readout of the Pivot-006 trial is brought forward by nearly a year.
$650m buys the group rights to RemeGen’s RC148.
After Aktis's $318m flotation Eikon is a bigger proposition.
ELVN-001 is made to look more like Terns’ TERN-701.
A pivotal trial will test the KRAS G12D degrader setidegrasib plus chemo in first-line PDAC.
Data from the Ilustro trial support the initiation of the phase 3 Lucerna study.
